According to the new guidelines, SGLT2 inhibitors are drugs with demonstrated cardiovascular and renal benefits irrespective of the presence of diabetes mellitus, which are recommended for patients with both reduced and preserved ejection fraction heart failure, as well as for patients with chronic kidney disease with eGFR ≥ 20 mL/min/1.72 m2 and proteinuria [41,42]. Here, SLC5A2 is linked to chronic kidney disease.